drugset / Trial / NCT01587040
Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Primary Objective: The purpose of this study was to determine the long term safety and tolerability of SAR245408 and SAR245409 as a monotherapy or as part of a combination regimen in participants who were benefiting from treatment.
Timeline
- Start
- 2012-07-20
- Primary completion
- 2018-05-23
- Completion
- 2018-05-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | pilaralisib | Small molecule | 400 mg | Oral |
| Subject | voxtalisib | Small molecule | 50 mg | Oral |